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The diuretic drug amiloride, an inhibitor of Nat uptake, competitively inhibits the catalytic activity of the 
urokinase-type plasminogen activator (u-PA), with a Ki of 7 x 10e6 M. Generation of plasmin, cleavage of
peptide substrates, and interaction of u-PA with a specific macromolecular proteinase inhibitor are all pre- 
vented in the presence of the drug. In contrast, amiloride does not affect the activity of either tissue-type 
plasminogen activator, plasmin, plasma kallikrein or thrombin. The inhibition of u-PA by amiloride may 
be related to the previously reported inhibition of u-PA-type enzymes by Na+. Amiloride or related com- 
pounds could prove useful in selectively controlling u-PA-catalyzed extracellular proteolysis. 
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1. INTRODUCTION 
The conversion of the zymogen plasminogen in- 
to plasmin, a trypsin-like extracellular protease of 
broad substrate specificity, is catalyzed by 
plasminogen activators (PAS). Two distinct PAS 
have been identified in mammals: urokinase-type 
PA (u-PA) and tissue-type PA (t-PA). The two 
PAS are the products of different genes [1,2], but 
they share a number of structural and catalytic 
properties. However, important functional dif- 
ferences between these enzymes have recently been 
demonstrated: t-PA binds to fibrin and to other 
components of extracellular matrices, and this in- 
teraction can dramatically increase its catalytic ac- 
tivity [3,4]; in contrast, u-PA binds to a specific 
plasma membrane receptor [5], a configuration 
which focalizes its activity to the close environment 
of the cell surface. Thus it is likely that the two en- 
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zymes play distinct roles in the generation of ex- 
tracellular proteolysis (for a recent review on PAS, 
see [6]). 
A wide variety of cell types synthesize and 
secrete one, the other, or in some cases both types 
of PAS. Cellular production of these enzymes is 
often associated with physiological and pathologi- 
cal processes involving cell migration and tissue 
remodelling, for instance in the context of ovula- 
tion [7], embryo implantation [8], mammary gland 
involution [9], inflammatory reactions [lo], tumor 
invasion and metastasis [ 111, etc. The availability 
of specific inhibitors of one or the other PA would 
help in elucidating the role of these enzymes, and 
in controlling extracellular proteolysis when 
desirable. Besides specific antibodies that have 
been raised against the two enzymes, no phar- 
macological agent that selectively inhibits the ac- 
tivity of one or the other PA has been described. 
In this context, the inhibition of u-PA-type en- 
zymes by physiological concentrations of NaCl 
[12-141 suggests an avenue of investigation for the 
development of specific inhibitors of u-PA. 
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We report here that amiloride, an inhibitor of 
Na+ transport [ 151, competitively inhibits the 
catalytic activity of u-PA, without decreasing 
those of t-PA, or of plasmin. Thus, amiloride may 
be a useful model compound for the development 
of u-PA-specific protease inhibitors. 
2. MATERIALS AND METHODS 
High-M, (55 000) u-PA was obtained from the 
Green Cross Corporation (Osaka, Japan), human 
thrombin (T 6759) and amiloride (A 7410) from 
Sigma (St. Louis, MO). Low-M, (33 000) u-PA, 
single chain t-PA, and human plasma kallikrein 
were the kind gifts of Serono (Denens, Switzer- 
land), J. Morser (Codon, South San Francisco, 
CA), and M. Schapira (Division de Rhumatologie, 
Hiipital Cantonal, Geneva, Switzerland), respec- 
tively. Plasminogen was purified from outdated 
human plasma by lysine-Sepharose (Pharmacia 
Fine Chemicals, Piscataway, NJ) affinity chroma- 
tography [16]. CNBr fragments of fibrinogen, 
prepared as described [17], were the gift of G. 
Reber (Division d’HCmostase, HBpital Cantonal, 
Gentve). 
The thiobenzyl benzyloxycarbonyl-L-lysinate 
assay for trypsin-like enzymes was performed as 
described [18], using a substrate concentration of 
7.3 x lo-’ M . N-Benzyloxycarbonyl-L-lysine 
thiobenzyl ester and 5,5 ‘-dithio-bis-(2-nitroben- 
zoic acid) were obtained from Calbiochem (La 
Jolla, CA). 
The zymographic assay for PAS was performed 
as described [191. As a source of murine u-PA and 
t-PA, we used the serum-free conditioned medium 
of MSV-3T3 1201 and PYS (a mouse parietal yolk 
sac-like [21] cell line that produces a PA elec- 
trophoretically, catalytically and immunologically 
related to t-PA, and not to u-PA) cell cultures, 
respectively. 
Reaction of ‘251-u-PA with the PA-specific in- 
hibitor of U-937 cells was analyzed as described 
1191. 
Hydrolysis of L-pyroglutamyl-glycyl-L-argi- 
nine-p-nitroanilide (S-2444) and D-valyl-L-glycyl- 
L-arginine-p-nitroanilide (S-2322) (KabiDiagnos- 
tica, Stockholm, Sweden) was monitored by fol- 
lowing the increase in absorbance at 405 nm, 




To test for a possible effect of amiloride on the 
catalytic activity of PAS, we used a calorimetric 
assay based on the cleavage of a general substrate 
for trypsin-like proteases. Amiloride inhibited the 
u-PA-catalyzed hydrolysis of this compound, but 
it did not affect the activity of the other enzymes 
tested (fig.1). In particular, neither plasmin, 
generated from plasminogen in the presence of t- 
PA, nor t-PA was affected by amiloride, even in 
the presence of fibrinogen peptides, which enhance 
the activation of plasminogen by t-PA [17]. 
The selective inhibition by amiloride of u-PA- 
catalyzed plasminogen activation was next 
demonstrated using a zymographic assay. In this 
assay, PAS diffusing out of a polyacrylamide gel 
activate the plasminogen present in a layer of in- 
soluble protein substrate; the plasmin thus 
generated causes localized lysis of the substrate. 
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Fig. 1. Thiobenzyl benzyloxycarbonyl-L-lysinate assay. 
The rate of substrate lysis catalyzed by u-PA (A4r 33000, 
0.3 Kg/ml), t-PA (0.6 pg/ml), t-PA (0.6 fig/ml) + CNBr 
fibrinogen fragments (200 yg/ml) (T-PA + f), t-PA 
(0.02 pg/ml) + CNBr fibrinogen fragments (2OOrg/ 
ml) + plasminogen (1 pg/ml) (T-PA + f + pgn), throm- 
bin (0.1 pg/ml), and kallikrein (0.3 pg/ml) tias deter- 
mined in the presence of increasing concentrations of 
amiloride. For each enzyme, results are expressed as 070 
of the rate of substrate lysis in the absence of amiloride. 
For kallikrein, plasmin, thrombin and u-PA, reactivities 
towards thiobenzyl benzyloxycarbonyl-L-lysinate have 
been compared and found to be very similar [ 181; in the 
case of thrombin and u-PA, Km values were reported to 
be 4 x lo-’ M and 3 x IO-' M, respectively. 
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to SDS-PAGE, and the gels were deposited onto 
plasminogen-containing casein substrate layers 
(fig.2). When amiloride was included in the 
substrate, the apparition of lytic zones was 
markedly retarded in the samples containing both 
high- and low it& forms of human u-PA, as well as 
in that containing murine u-PA. In contrast, the 
lysis areas catalyzed by either human or murine t- 
PA were of comparable size in the presence or 
absence of amiloride. This confirms that amiloride 
specifically inhibits the activation of plasminogen 
by u-PA-type enzymes, without affecting the ac- 
tivity of t-PAS or of plasmin. 
In addition to catalytically activating plasmi- 
nogen, u-PA may also react stoichiometrically 
with protease inhibitors and form covalent, inac- 
tive, enzyme-inhibitor complexes. To determine 
whether amiloride also prevented reaction of u-PA 
with such an inhibitor, 1Z51-~-PA was added to 
conditioned medium from a culture of monocyte- 
like U-937 cells, which produce a high affinity, 
PA-specific, protease inhibitor [19]. Amiloride 
prevented the formation of a 72 kDa u-PA- 
inhibitor complex (fig.3). This demonstrated that 
amiloride inhibits not only the catalytic activity of 
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Fig.2. Zymographic assay of PAS. Equivalent catalytic 
amounts (0.1 Ploug units) of 55 kDa human u-PA (lanes 
l), 33 kDa human u-PA (lanes 2), human t-PA (lanes 3), 
murine u-PA (lanes 4) and murine t-PA (lanes 5) were 
subjected to SDS-PAGE. The electrophoretic gels were 
layered onto casein-agar-plasminogen substrate gels; 
amiloride (1 mM) was included in one of the substrate 
gels (right panel). Photographs were taken under dark- 
ground illumination, after 3 h of incubation at 37°C. 
The molecular masses of marker proteins, electro- 
phoresed in adjacent lanes and stained with Coomassie 
I 
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Fig.4. Lineweaver-Burk plot of initial reaction velocity, 
Fe, versus substrate concentration, S, of u-PA-catalyzed 
hydrolysis of L-pyroglutamyl-glycyl-L-arginine-p-nitro- 
anilide, in the presence and absence of amiloride. The 
concentrations of amiloride used are indicated on the 
graph. K,,, in this experiment: 4 x lo-’ M; Ki = 7 x 
blue, are indicated. 1o-6 M. 
u-PA on plasminogen, but also its reaction with 
macromolecular antiproteases. 
Finally, the mode of inhibition of u-PA by 
amiloride was investigated using L-pyroglutamyl- 
33 Kd - 
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Fig.3. Autoradiographic analysis of u-PA-inhibitor 
complex formation. Amiloride (0.2 mM final 
concentration) was added to fresh serum-free culture 
medium and to inhibitor-rich conditioned medium from 
U-937 cells. 33 kDa 1251-~-PA (2 ng) was then added to 
10~1 samples of fresh medium (lane l), amiloride- 
containing fresh medium (lane 2), conditioned medium 
(lane 3), and amiloride-containing conditioned medium 
(lane 4). After 1 h at 4”C, the samples were subjected to 
SDS-PAGE, and the gel was analyzed by 
autoradiography. 
189 
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glycyl-L-arginine-p-nitroanilide, a chromogenic 
peptide substrate for the enzyme. A Lineweaver- 
Burk plot (fig.4) of the data demonstrated that the 
inhibition is competitive, with a Ki of 7 x 10m6 M. 
Concentrations of amiloride up to 1 x 1O-3 M did 
not inhibit cleavage of this substrate, nor that of 
D-valyl-L-glycyl-L-arginine-p-nitroanilide, by t- 
PA. 
4. DISCUSSION 
We have shown here that amiloride competitive- 
ly inhibits the catalytic activity of u-PA on a varie- 
ty of substrates, including plasminogen, its natural 
macromolecular target. This appears to be related 
to a general property of the catalytic domain of u- 
PA-type enzymes, since human, murine and por- 
cine (not shown) U-PAS were similarly affected. 
The non-catalytic A-chain of the enzyme is not im- 
plicated in this phenomenon since both high-Mr u- 
PA and low-M, u-PA (a cleavage product that 
lacks most of the A-chain but retains full catalytic 
activity [22]) were inhibited by amiloride. The 
selectivity of this inhibition is illustrated by the 
lack of effect of amiloride on t-PA-catalyzed 
cleavage of both plasminogen and synthetic 
substrates. In fact, of the serine proteases tested in 
the present work, which belong to the coagulation, 
kinin formation, and fibrinolytic pathways, only 
u-PA was inhibited by amiloride. 
Macromolecular antiproteases that are essential- 
ly PA specific, i.e. PA-I 1 and PA-I 2, have recent- 
ly been identified and characterized [23,24]; unlike 
amiloride, these proteins, which belong to the ser- 
pin family of antiproteases and are produced by 
endothelial cells and mononuclear phagocytes 
respectively, inhibit both u-PA and t-PA. 
The guanidino group of amiloride is probably 
involved in its inhibitory activity; indeed, another 
compound that contains this functional group, i.e. 
p-nitro-guanidino-benzoate, is a very potent in- 
hibitor of tryptic proteases, including u-PA [12]. 
The selective inhibition of u-PA by the Na+ 
transport blocker amiloride may in some way be 
related to the inhibition of this enzyme, but not of 
most other tryptic proteases, by relatively low con- 
centrations of NaC [ 12- 141. This contention is sup- 
ported by the fact that urinary kallikrein, a 
trypsin-like serine protease of similar catalytic 
specificity but with a different preferred 
190 
macromolecular substrate (i.e. kininogens), is also 
inhibited by both Na+ and amiloride [25,26]; 
however, it must be noted that inhibition of 
urinary kallikrein by amiloride is a controversial 
issue [27], and that the mode of kallikrein inhibi- 
tion by amiloride was reported to be non- 
competitive [25]. 
In conclusion, our results suggest that  study of 
amiloride analogs, as well as of other agents 
known to affect transport and other aspects of 
Na+ metabolism, may reveal interesting com- 
pounds that could be used to control u-PA- 
catalyzed proteolysis. Indeed, although amiloride 
itself may not be specific enough to be useful as an 
anti-u-PA in vivo, a drug that would block the ac- 
tivation of plasminogen by u-PA, without affec- 
ting the activity of t-PA or of plasmin, could be a 
valuable therapeutic tool. 
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